HomeIMCR • NASDAQ
add
Immunocore Holdings PLC - ADR
Previous close
$31.91
Day range
$30.54 - $32.22
Year range
$23.15 - $39.33
Market cap
1.57B USD
Avg Volume
324.42K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 97.96M | 29.93% |
Operating expense | 42.79M | 10.75% |
Net income | -10.30M | 11.33% |
Net profit margin | -10.51 | 31.80% |
Earnings per share | -0.20 | 13.04% |
EBITDA | -14.10M | 6.19% |
Effective tax rate | -6.25% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 882.81M | 2.70% |
Total assets | 1.08B | 5.77% |
Total liabilities | 693.91M | 4.47% |
Total equity | 388.48M | — |
Shares outstanding | 50.39M | — |
Price to book | 4.14 | — |
Return on assets | -3.52% | — |
Return on capital | -4.54% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -10.30M | 11.33% |
Cash from operations | 25.96M | 10.62% |
Cash from investing | -30.41M | 91.32% |
Cash from financing | 3.67M | 548.66% |
Net change in cash | 11.09M | 103.38% |
Free cash flow | 12.10M | -48.73% |
About
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology. Wikipedia
Founded
2008
Website
Employees
493
